FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2556555941> ?p ?o ?g. }

• W2556555941 abstract "Abstract OBJECTIVES: Pleural and pericardial effusions can lead to severe outcomes. Cancer accounts for an estimated 40% of all pleural effusions. About half of the effusions diagnosed in cancer patients are malignant, while the rest are nonmalignant and may occur as complications of the cancer treatments themselves. Pleural and pericardial effusions are associated with increased morbidity and mortality as well as high healthcare costs. The objective of this study was to review the economic burden of pleural and pericardial effusions in cancer patients. METHODS: A systematic search of the English-language medical literature published between 1990 and 2006 was conducted. Additional publications and conference proceedings were retrieved from the article bibliographies and included in the review. Articles selected include prospective or retrospective studies specifically designed to examine burden of illness, direct medical costs, indirect costs, or cost drivers associated with pleural or pericardial effusions in cancer patients. All original costs were reported, with adjusted figures (to 2006 US dollars) presented in parentheses using the medical care component of the consumer price index from the US Bureau of Labor Statistics. RESULTS: Of 15 studies identified, 11 met selection criteria and were reviewed in detail. Seven references reported data on costs associated with pleural or pericardial effusions in cancer patients. The cost per episode of pleural effusion ranged from $3,391 (2006 US $4,387) for outpatient treatment with pleural catheter to $20,996 ($37,341) for talc pleurodesis. The most common treatment for malignant pleural effusion is chest tube insertion and drainage with instillation of a sclerosing agent. Key cost drivers for significant pleural effusions included operating room costs, surgeon fees, and drugs such as sclerosing agents. Resources used for management of low grade pleural effusions include chest x-rays, physician outpatient visits, diuretics, and corticosteroids. For the treatment of pericardial effusion, the costs of performing pericardiocentesis and a pericardial window procedure were estimated to be $4,446 and $14,641 (2006 US$), respectively. Cost components for pericardial effusions, depending on treatment modality selected, included echocardiogram (3–10%), intensive care unit (17–56%), sclerosant (1–4%), surgeon fees (28–29%), anesthesia fees (20%), and operating room costs (31%). CONCLUSIONS: Pleural and pericardial effusions lead to significant direct medical costs, contributing to the total cost of care among patients treated for cancer. These costs should be included in the economic evaluation of therapies that increase the risk of pleural and pericardial effusions. Given the scarcity of published analyses in this area, additional research is warranted to better understand the burden of pleural and pericardial effusions." @default.
• W2556555941 created "2016-11-30" @default.
• W2556555941 creator A5024580938 @default.
• W2556555941 creator A5035272901 @default.
• W2556555941 creator A5046622222 @default.
• W2556555941 creator A5087184017 @default.
• W2556555941 date "2006-11-16" @default.
• W2556555941 modified "2023-09-28" @default.
• W2556555941 title "A Review of the Economic Burden of Pleural and Pericardial Effusions in Cancer Patients." @default.
• W2556555941 doi "https://doi.org/10.1182/blood.v108.11.5514.5514" @default.
• W2556555941 hasPublicationYear "2006" @default.
• W2556555941 type Work @default.
• W2556555941 sameAs 2556555941 @default.
• W2556555941 citedByCount "0" @default.
• W2556555941 crossrefType "journal-article" @default.
• W2556555941 hasAuthorship W2556555941A5024580938 @default.
• W2556555941 hasAuthorship W2556555941A5035272901 @default.
• W2556555941 hasAuthorship W2556555941A5046622222 @default.
• W2556555941 hasAuthorship W2556555941A5087184017 @default.
• W2556555941 hasConcept C121608353 @default.
• W2556555941 hasConcept C126322002 @default.
• W2556555941 hasConcept C141071460 @default.
• W2556555941 hasConcept C142724271 @default.
• W2556555941 hasConcept C2776979038 @default.
• W2556555941 hasConcept C2777407522 @default.
• W2556555941 hasConcept C2779634585 @default.
• W2556555941 hasConcept C2781175549 @default.
• W2556555941 hasConcept C71924100 @default.
• W2556555941 hasConceptScore W2556555941C121608353 @default.
• W2556555941 hasConceptScore W2556555941C126322002 @default.
• W2556555941 hasConceptScore W2556555941C141071460 @default.
• W2556555941 hasConceptScore W2556555941C142724271 @default.
• W2556555941 hasConceptScore W2556555941C2776979038 @default.
• W2556555941 hasConceptScore W2556555941C2777407522 @default.
• W2556555941 hasConceptScore W2556555941C2779634585 @default.
• W2556555941 hasConceptScore W2556555941C2781175549 @default.
• W2556555941 hasConceptScore W2556555941C71924100 @default.
• W2556555941 hasLocation W25565559411 @default.
• W2556555941 hasOpenAccess W2556555941 @default.
• W2556555941 hasPrimaryLocation W25565559411 @default.
• W2556555941 hasRelatedWork W138749830 @default.
• W2556555941 hasRelatedWork W1800520966 @default.
• W2556555941 hasRelatedWork W1861220207 @default.
• W2556555941 hasRelatedWork W2146944342 @default.
• W2556555941 hasRelatedWork W2152715776 @default.
• W2556555941 hasRelatedWork W2556555941 @default.
• W2556555941 hasRelatedWork W2579000779 @default.
• W2556555941 hasRelatedWork W2904791485 @default.
• W2556555941 hasRelatedWork W2943945018 @default.
• W2556555941 hasRelatedWork W4243592654 @default.
• W2556555941 isParatext "false" @default.
• W2556555941 isRetracted "false" @default.
• W2556555941 magId "2556555941" @default.
• W2556555941 workType "article" @default.